On August 27, the European Commission announced that Novartis CAR-T cell therapy Kymriah has been approved to treat pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in Europe.
On Saturday, July 21 we had the pleasure of attending the 27th Annual Glenn O. Hawbaker Charity Golf Tournament at Penn State Blue and White Courses in State College, Pa. The Emily Whitehead Foundation was invited to participate as one of eight beneficiaries of this year's tournament.
On Friday, July 13 we hosted our 4th annual "Tee Off for T-Cells" golf tournament at Philipsburg Elks Lodge and Country Club in our hometown of Philipsburg, Pa. This year's event was our most successful yet and raised over $66,000!
It was on this day six years ago that we learned the T-cell therapy had not only saved Emily's life, but also left no evidence of leukemia cells. She was free of cancer, and Kari and I didn’t have to find out what it would be like living without our only daughter.
Dr. Carl June Named One of TIME’s 100 Most Influential People of 2018—Emily Whitehead Writes Tribute
Dr. Carl June, Penn Medicine, has been named one of TIME Magazine's 100 most influential people in the world. As a surprise to Dr. June, Emily Whitehead was asked to write a brief tribute for the 2018 TIME 100 issue.